Compare AstraZeneca plc (AZN) vs Costco Wholesale Corporation (COST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Costco Wholesale Corporation — how do they compare? AstraZeneca plc trades at $157.75 (market cap $248.14B), while Costco Wholesale Corporation trades at $942.51 (market cap $418.79B). The key difference: Costco Wholesale Corporation is the larger of the two by market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | COST | |
|---|---|---|
Market Cap | $248.14B | $418.79B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $1.09K |
52-Week Low | $147.06 | $849.63 |
Enterprise Value | $275.41B | $406.93B |
Dividend Yield | 2.01% | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
COST trades at $952.75, up 0.52% today, with a neutral technical signal. The stock shows strong fundamentals, including revenue growth to $275.24B in 2025 and consistent earnings beats, though Q1 2026 missed estimates. Positive sentiment is driven by a 65.52% analyst buy rating and a consensus price target of $1,120. Recent news highlights membership fee hikes and robust March sales, supporting investor confidence.
Outlook remains favorable due to steady growth and high institutional ownership, but risks include elevated valuation (P/E 47.5) and competitive pressures. The stock offers long-term potential if earnings momentum continues, though near-term volatility may persist amid market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →
